ATP-sensitive potassium (K(ATP)) channel openers diazoxide and nicorandil lower intraocular pressure by activating the Erk1/2 signaling pathway

por Roy Chowdhury, Uttio, Bahler, Cindy K., Holman, Bradley H., Fautsch, Michael P.
Publicado no PLoS One (2017)

HUMAN CORNEAL ENDOTHELIAL CELL TRANSPLANTATION IN A HUMAN EX VIVO MODEL

por Patel, Sanjay V., Bachman, Lori A., Hann, Cheryl R., Bahler, Cindy K., Fautsch, Michael P.
Publicado em 2009

Prostaglandins Increase Trabecular Meshwork Outflow Facility in Cultured Human Anterior Segments

por Bahler, Cindy K., Howell, Kyle G., Hann, Cheryl R., Fautsch, Michael P., Johnson, Douglas H.
Publicado em 2007

Ocular Hypotensive Effects of the ATP-Sensitive Potassium Channel Opener Cromakalim in Human and Murine Experimental Model Systems

por Roy Chowdhury, Uttio, Bahler, Cindy K., Holman, Bradley H., Dosa, Peter I., Fautsch, Michael P.
Publicado no PLoS One (2015)

Correction: Ocular Hypotensive Effects of the ATP-Sensitive Potassium Channel Opener Cromakalim in Human and Murine Experimental Model Systems

por Roy Chowdhury, Uttio, Bahler, Cindy K., Holman, Bradley H., Dosa, Peter I., Fautsch, Michael P.
Publicado no PLoS One (2015)

Isolation and characterization of novel primary cells from the human distal outflow pathway

por Roy Chowdhury, Uttio, Bahler, Cindy K., Hann, Cheryl R., Holman, Bradley H., Fautsch, Michael P.
Publicado no Sci Rep (2021)

ATP-Sensitive Potassium (K(ATP)) Channel Activation Decreases Intraocular Pressure in the Anterior Chamber of the Eye

por Chowdhury, Uttio Roy, Bahler, Cindy K., Hann, Cheryl R., Chang, Minhwang, Resch, Zachary T., Romero, Michael F., Fautsch, Michael P.
Publicado em 2011

CHARACTERIZATION OF MONOCLONAL ANTIBODIES AGAINST THE GLAUCOMA-ASSOCIATED PROTEIN MYOCILIN

por Ezzat, Mohamed-Karim, Howell, Kyle G., Bahler, Cindy K., Beito, Thomas G., Loewen, Nils, Poeschla, Eric M., Fautsch, Michael P.
Publicado em 2008

Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure–Lowering Effects of Latanoprost

por Roddy, Gavin W., Viker, Kimberly B., Winkler, Nelson S., Bahler, Cindy K., Holman, Bradley H., Sheikh-Hamad, David, Roy Chowdhury, Uttio, Stamer, W. Daniel, Fautsch, Michael P.
Publicado no Invest Ophthalmol Vis Sci (2017)

Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits

por Roy Chowdhury, Uttio, Kudgus, Rachel A., Rinkoski, Tommy A., Holman, Bradley H., Bahler, Cindy K., Hann, Cheryl R., Reid, Joel M., Dosa, Peter I., Fautsch, Michael P.
Publicado no PLoS One (2020)

Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents

por Roy Chowdhury, Uttio, Rinkoski, Tommy A., Bahler, Cindy K., Millar, J. Cameron, Bertrand, Jacques A., Holman, Bradley H., Sherwood, Joseph M., Overby, Darryl R., Stoltz, Kristen L., Dosa, Peter I., Fautsch, Michael P.
Publicado no Invest Ophthalmol Vis Sci (2017)

Pharmacological Profile and Ocular Hypotensive Effects of Cromakalim Prodrug 1, a Novel ATP-Sensitive Potassium Channel Opener, in Normotensive Dogs and Nonhuman Primates

por Roy Chowdhury, Uttio, Kudgus, Rachel A., Holman, Bradley H., Rinkoski, Tommy A., Hann, Cheryl R., Bahler, Cindy K., McCloud, Eric, Appt, Susan E., Reid, Joel M., Dosa, Peter I., Fautsch, Michael P.
Publicado no J Ocul Pharmacol Ther (2021)